203 related articles for article (PubMed ID: 34615996)
1. BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade.
Tong J; Tan X; Risnik D; Gao M; Song X; Ermine K; Shen L; Wang S; Yu J; Zhang L
Oncogene; 2021 Dec; 40(48):6566-6578. PubMed ID: 34615996
[TBL] [Abstract][Full Text] [Related]
2. BET Inhibitors Potentiate Chemotherapy and Killing of
Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
[TBL] [Abstract][Full Text] [Related]
3. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.
Kuang C; Tong J; Ermine K; Cai M; Dai F; Hao S; Giles F; Huang Y; Yu J; Zhang L
Front Oncol; 2022; 12():1018775. PubMed ID: 36313707
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade.
Tong J; Tan X; Song X; Gao M; Risnik D; Hao S; Ermine K; Wang P; Li H; Huang Y; Yu J; Zhang L
Cancer Res; 2022 Apr; 82(7):1340-1352. PubMed ID: 35149588
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
8. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.
Devetzi M; Kosmidou V; Vlassi M; Perysinakis I; Aggeli C; Choreftaki T; Zografos GN; Pintzas A
Sci Rep; 2016 Nov; 6():36532. PubMed ID: 27827395
[TBL] [Abstract][Full Text] [Related]
9. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
10. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis.
Shi C; Zhang H; Wang P; Wang K; Xu D; Wang H; Yin L; Zhang S; Zhang Y
Cell Death Dis; 2019 Oct; 10(11):815. PubMed ID: 31653826
[TBL] [Abstract][Full Text] [Related]
11. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
12. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
13. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation.
Chen L; Hao M; Yan J; Sun L; Tai G; Cheng H; Zhou Y
J Biol Chem; 2021; 296():100515. PubMed ID: 33676890
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
16. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
17. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
Zhang D; Zhao L; Shen Q; Lv Q; Jin M; Ma H; Nie X; Zheng X; Huang S; Zhou P; Wu G; Zhang T
Int J Cancer; 2017 May; 140(10):2298-2309. PubMed ID: 28213952
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
Uddin S; Hussain AR; Ahmed M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Pathol; 2011 Dec; 179(6):3032-44. PubMed ID: 21978492
[TBL] [Abstract][Full Text] [Related]
20. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Fiskus W; Mill CP; Perera D; Birdwell C; Deng Q; Yang H; Lara BH; Jain N; Burger J; Ferrajoli A; Davis JA; Saenz DT; Jin W; Coarfa C; Crews CM; Green MR; Khoury JD; Bhalla KN
Leukemia; 2021 Sep; 35(9):2621-2634. PubMed ID: 33654205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
